IRVINE, Calif. — January 10, 2023 — Immunis, Inc., a private biotech company generating a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present at the annual Biotech Showcasein San Francisco. Dr. Keirstead will share the latest advancements of Immunis’ investigational secretome product, STEM, highlighting the Phase 1/2a clinical trial’s first-in-human injection milestone.

Biotech Showcase is an international conference highlighting cutting-edge technologies from over 400 companies, across 35 countries. The conference provides a platform for top leaders in scientific innovation and is reputed as one of the greatest conferences for biotech investment opportunities. We are delighted that Dr. Keirstead will be sharing Immunis’ novel stem cell secretome technology with some of the greatest scientific visionaries of the world.

About Biotech Showcase

Biotech Showcase is a three-day investor conference designed for partnering opportunities, panel discussions and presentations among the world’s top innovators. For more information about Biotech Showcase please visit: www.informaconnect.com/biotech-showcase/

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.